Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2055-2064

  Lee, Dhong Hyun ^a   Qi, Jun ^b   Bradner, James E ^b   Said, Jonathan W ^c   Doan, Ngan B ^c   Forscher, Charles ^a   Yang, Henry ^d   Koeffler, H Phillip ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Santa Monica UCLA Medical Center   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

JQ1; Osteosarcoma; Rapamycin; RUNX2; Synergism

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN CONTAINING PROTEIN 4; MYC PROTEIN; PROTEIN P21; RAPAMYCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NUCLEAR PROTEIN; RUNX2 PROTEIN, HUMAN; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TRANSCRIPTION INITIATION SITE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; ONCOGENE MYC; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENES, MYC; HUMANS; MICE; MICE, NUDE; NUCLEAR PROTEINS; OSTEOSARCOMA; SIROLIMUS; TRANSCRIPTION FACTORS; TRANSCRIPTION INITIATION SITE; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923164412     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29269     Document Type: Article

References (31)

1. Andreoli F, Barbosa AJ, Parenti MD, et al. Modulation of epigenetic targets for anticancer therapy: Clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 2013;19: 578-613.
2. Lockwood WW, Zejnullahu K, Bradner JE, et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 2012;109: 19408-13.
3. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol 2008;28: 967-76.
4. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73.
5. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478: 524-8.
6. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904-17.
7. Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in highrisk acute lymphoblastic leukemia. Blood 2012; 120: 2843-52.
8. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
9. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013;3: 308-23.
10. Bandopadhayay P, Bergthold G, Nguyen B, et al. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. Clin Cancer Res 2014;20: 912-25.
11. Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma 2012;2012: 627254.
12. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18: 1926-45.
13. Bogenmann E, Moghadam H, DeClerck YA, et al. c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res 1987;47: 3808-14.
14. Lee DH, Thoennissen NH, Goff C, et al. Synergistic effect of low-dose cucurbitacin B and lowdose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011;306: 161-70.
15. Lee DH, Amanat S, Goff C, et al. Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis 2013;2: E47.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22: 27-55.
17. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70: 440-6.
18. Luong QT, O'Kelly J, Braunstein GD, et al. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006;12: 5570-7.
19. Abramoff MDM, Magalhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics Int 2004;11: 7.
20. Chua SW, Vijayakumar P, Nissom PM, et al. A novel normalization method for effective removal of systematic variation in microarray data. Nucleic Acids Res 2006;34: E38.
21. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102: 15545-50.
22. Zhang YW, Yasui N, Ito K, et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA 2000;97: 10549-54.
23. Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 2009;185: 203-11.
24. Consortium EP. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004;306: 636-40.
25. Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of superenhancers. Cell 2013;153: 320-34.
26. Whyte WA, Orlando DA, Hnisz D, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013;153: 307-19.
27. Westendorf JJ, Zaidi SK, Cascino JE, et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002;22: 7982-92.
28. Martin JW, Zielenska M, Stein GS, et al. The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011;2011: 282745.
29. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3: 859-68.
30. Lucero CM, Vega OA, Osorio MM, et al. The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol 2013;228: 714-23.
31. Lamoureux F, Baud'huin M, Rodriguez Calleja L, et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the boneassociated tumour vicious cycle. Nat Commun 2014;5: 3511.